Dimensional Fund Advisors
RYTM icon

Dimensional Fund Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Dimensional Fund Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Sell
18,973
-178
-0.9% -$16.1K ﹤0.01% 2732
2026
Q1 		$1.67M Sell
19,151
-12,867
-40% -$1.25M ﹤0.01% 2744
2025
Q4 		$3.43M Buy
32,018
+3,640
+13% +$386K ﹤0.01% 2624
2025
Q3 		$2.87M Buy
+28,378
New +$2.63M ﹤0.01% 2671
2024
Q1 		– Sell
-96,948
Closed -$4.46M – 3428
2023
Q4 		$4.46M Hold
96,948
– – ﹤0.01% 2591
2023
Q3 		$2.22M Sell
96,948
-7,010
-7% -$157K ﹤0.01% 2748
2023
Q2 		$1.71M Sell
103,958
-20,551
-17% -$371K ﹤0.01% 2817
2023
Q1 		$2.22M Buy
+124,509
New +$3.13M ﹤0.01% 2721
2022
Q3 		$5.47M Sell
223,131
-30,110
-12% -$560K ﹤0.01% 2395
2022
Q2 		$1.05M Buy
253,241
+59,532
+31% +$326K ﹤0.01% 2904
2022
Q1 		$2.23M Buy
193,709
+34,840
+22% +$306K ﹤0.01% 2800
2021
Q4 		$1.59M Sell
158,869
-21,576
-12% -$242K ﹤0.01% 2909
2021
Q3 		$2.36M Sell
180,445
-109,825
-38% -$1.68M ﹤0.01% 2811
2021
Q2 		$5.68M Sell
290,270
-18,303
-6% -$380K ﹤0.01% 2573
2021
Q1 		$6.57M Sell
308,573
-31,084
-9% -$902K ﹤0.01% 2479
2020
Q4 		$10.1M Buy
339,657
+4,843
+1% +$123K ﹤0.01% 2285
2020
Q3 		$7.26M Buy
334,814
+12,179
+4% +$279K ﹤0.01% 2338
2020
Q2 		$7.19M Buy
322,635
+54,104
+20% +$1.05M ﹤0.01% 2334
2020
Q1 		$4.09M Sell
268,531
-4,015
-1% -$71.9K ﹤0.01% 2487
2019
Q4 		$6.26M Buy
272,546
+13,032
+5% +$290K ﹤0.01% 2528
2019
Q3 		$5.6M Buy
259,514
+45,497
+21% +$976K ﹤0.01% 2562
2019
Q2 		$4.71M Buy
214,017
+116,406
+119% +$2.94M ﹤0.01% 2653
2019
Q1 		$2.68M Buy
97,611
+43,787
+81% +$1.26M ﹤0.01% 2825
2018
Q4 		$1.45M Buy
+53,824
New +$1.49M ﹤0.01% 2939

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dimensional Fund Advisors's RYTM Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 0.93% in Q2 2026, selling an estimated $16.1K and leaving 18,973 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2732.

Dimensional Fund Advisors first reported a position in RYTM in Q4 2018 and has held it in 24 quarters since. The position peaked at $10.1M in Q4 2020. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Dimensional Fund Advisors held 18,973 shares of Rhythm Pharmaceuticals worth $2.11M as of Q2 2026.
  • Dimensional Fund Advisors sold 178 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $16.1K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2732 holding.
  • Dimensional Fund Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2018 and has held it in 24 quarters since.
  • Dimensional Fund Advisors's Rhythm Pharmaceuticals position peaked at $10.1M in Q4 2020.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.